|

BI 764532 Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Obrixtamig

Pipeline

Phase 1: 2

Top Sponsors

  • Boehringer Ingelheim2

Indications

  • Neuroendocrine Neoplasms2
  • Cancer2
  • Small Cell Lung Carcinoma (SCLC)1
  • Lung Cancer1

Other1 trial

A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer
Phase 1

Miami, Florida1 trial

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

University of Miami

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.